Skip to main content
Fig. 2 | Journal for ImmunoTherapy of Cancer

Fig. 2

From: A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors

Fig. 2

TCR expansion in peripheral blood in a cohort of patients treated for 1 cycle (4 weeks) with utomilumab single-agent [22] vs patients treated with utomilumab/mogamulizumab. Individual TCR sequences were considered to have expanded after treatment if frequencies in on-treatment specimens were greater than normal biologic time-dependent variance as determined by a beta binomial model [28]. Box plot provides median and 25%/75% quartiles with whiskers to the last data point within 1.5× the IQR. CI, confidence interval; IQR, interquartile range; Moga, mogamulizumab; TCR, T-cell receptor; Uto, utomilumab

Back to article page